Among PARP inhibitors, olaparib (Ola, AZD 2281, AstraZeneca, London, UK) has been assessed in chemotherapy regimens for BRCA-mutated or HR-deficient breast and ovarian cancer, and several clinical trials are ongoing10, 11. Here, PARP1 is linked to ovarian cancer.